2 results
Approved WMORecruiting
Primary objective: To determine the efficacy of Sunitinib on the progression-free survival at 12 months in subjects with progressive malignant pheochromocytoma and paraganglioma treated with sunitinib at a starting dose of 37.5 mg daily (continuous…
Approved WMOCompleted
To evaluate the safety and tolerability of single ascending doses of UCB7853 administered as an iv infusion in healthy male study participantsTo evaluate the safety and tolerability of multiple (3 in total, given monthly) ascending doses of UCB7853…